+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Bronchitis Drugs Market by Drug Type, Patient Demographics, Formulation, Duration of Action, Mechanism of Action, Disease Severity, End-user, Route of Administration, Technology, Sales Channel, Treatment Duration - Global Forecast 2025-2030- Product Image
Bronchitis Drugs Market by Drug Type, Patient Demographics, Formulation, Duration of Action, Mechanism of Action, Disease Severity, End-user, Route of Administration, Technology, Sales Channel, Treatment Duration - Global Forecast 2025-2030- Product Image
Sale

Bronchitis Drugs Market by Drug Type, Patient Demographics, Formulation, Duration of Action, Mechanism of Action, Disease Severity, End-user, Route of Administration, Technology, Sales Channel, Treatment Duration - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 188 Pages
  • November 2024
  • Region: Global
  • 360iResearch™
  • ID: 6011464
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Bronchitis Drugs Market grew from USD 1.54 billion in 2023 to USD 1.68 billion in 2024. It is expected to continue growing at a CAGR of 9.74%, reaching USD 2.96 billion by 2030.

The bronchitis drugs market focuses on the development and commercialization of pharmaceuticals designed to treat both acute and chronic forms of bronchitis. These medications primarily include bronchodilators, steroids, antibiotics, and other symptomatic relief drugs. The necessity of bronchitis drugs arises due to the prevalence of respiratory conditions exacerbated by the increasing pollution levels, smoking habits, and seasonal respiratory infections. The demand is underscored by a significant aging population and a rise in cases of chronic obstructive pulmonary disease (COPD). Applications span from short-term acute bronchitis treatments to long-term chronic management, with end-uses across hospitals, clinics, and home care settings.

Key factors influencing market growth include advancements in drug formulations, strategic partnerships in drug development, and increasing awareness about respiratory health. Latest opportunities lie in personalized medicine approaches and innovative drug delivery systems like inhalers, which improve treatment efficacy and patient compliance. Investing in expanding geographic reach, especially in emerging markets with growing healthcare infrastructure, also presents a promising opportunity. However, market growth is challenged by stringent regulatory frameworks, side effects associated with prolonged drug usage, and competition from alternative treatments like herbal medicines.

Additionally, the rising adoption of digital health technologies necessitates innovation in telehealth integration for respiratory care management. Opportunities for innovation and research can be found in developing more potent combination therapies, minimizing side effects, and enhancing patient education programs about bronchitis management. The bronchitis drugs market is dynamic, characterized by rapid innovation and the need for robust clinical trials to substantiate drug efficacy. Understanding consumer behavior and fostering collaborations with healthcare providers could provide competitive advantages in this ever-evolving market landscape. Robust analytics and strategic planning are essential for businesses aiming to capture market share and sustain growth.

Understanding Market Dynamics in the Bronchitis Drugs Market

The Bronchitis Drugs Market is rapidly evolving, shaped by dynamic supply and demand trends. These insights provide companies with actionable intelligence to drive investments, develop strategies, and seize emerging opportunities. A comprehensive understanding of market dynamics also helps organizations mitigate political, geographical, technical, social, and economic risks while offering a clearer view of consumer behavior and its effects on manufacturing costs and purchasing decisions.
  • Market Drivers
    • Greater emphasis on preventive healthcare encouraging the development of prophylactic medications for bronchitis
    • Pharmaceutical companies focusing on strategic partnerships and collaborations to expand their market presence
    • Expansion of telemedicine and remote consultations easing accessibility to bronchitis management solutions
  • Market Restraints
    • Intense competition from over-the-counter remedies and alternative therapies reducing prescription drug growth
    • Limited awareness and varying diagnosis rates affecting the demand for bronchitis drugs across regions
    • Regulatory challenges and approval timelines slowing down the introduction of new bronchitis treatments
  • Market Opportunities
    • Developing combination drug formulations addressing multiple symptoms for enhanced patient compliance
    • Exploring untapped geographies with high incidences of bronchitis and limited drug accessibility
    • Capitalizing on the growing demand for natural and herbal bronchitis treatment alternatives
  • Market Challenges
    • Rising prices of raw materials affecting the profit margins of bronchitis pharmaceuticals companies
    • Potential side effects leading to reduced consumer trust in bronchitis medications
    • Navigating patent expirations and the associated risk of generic competition

Exploring Porter’s Five Forces for the Bronchitis Drugs Market

Porter’s Five Forces framework further strengthens the insights of the Bronchitis Drugs Market, delivering a clear and effective methodology for understanding the competitive landscape. This tool enables companies to evaluate their current competitive standing and explore strategic repositioning by assessing businesses’ power dynamics and market positioning. It is also instrumental in determining the profitability of new ventures, helping companies leverage their strengths, address weaknesses, and avoid potential pitfalls.

Applying PESTLE Analysis to the Bronchitis Drugs Market

External macro-environmental factors deeply influence the performance of the Bronchitis Drugs Market, and the PESTLE analysis provides a comprehensive framework for understanding these influences. By examining Political, Economic, Social, Technological, Legal, and Environmental elements, this analysis offers organizations critical insights into potential opportunities and risks. It also helps businesses anticipate changes in regulations, consumer behavior, and economic trends, enabling them to make informed, forward-looking decisions.

Analyzing Market Share in the Bronchitis Drugs Market

The Bronchitis Drugs Market share analysis evaluates vendor performance. This analysis provides a clear view of each vendor’s standing in the competitive landscape by comparing key metrics such as revenue, customer base, and other critical factors. Additionally, it highlights market concentration, fragmentation, and trends in consolidation, empowering vendors to make strategic decisions that enhance their market position.

Evaluating Vendor Success with the FPNV Positioning Matrix in the Bronchitis Drugs Market

The Bronchitis Drugs Market FPNV Positioning Matrix is crucial in evaluating vendors based on business strategy and product satisfaction levels. By segmenting vendors into four quadrants - Forefront (F), Pathfinder (P), Niche (N), and Vital (V) - this matrix helps users make well-informed decisions that best align with their unique needs and objectives in the market.

Strategic Recommendations for Success in the Bronchitis Drugs Market

The Bronchitis Drugs Market strategic analysis is essential for organizations aiming to strengthen their position in the global market. A comprehensive review of resources, capabilities, and performance helps businesses identify opportunities for improvement and growth. This approach empowers companies to navigate challenges in the increasingly competitive landscape, ensuring they capitalize on new opportunities and align with long-term success.

Key Company Profiles

The report delves into recent significant developments in the Bronchitis Drugs Market, highlighting leading vendors and their innovative profiles. These include Alembic Pharmaceuticals Ltd., Apotex Inc., Boehringer Ingelheim International GmbH, DLC Laboratories, Inc., Dr. Reddy's Laboratories Ltd., Fresenius Kabi, GlaxoSmithKline Pharmaceuticals Ltd., Glenmark Pharmaceuticals Ltd., Jamp Pharma Corporation, Marlex Pharmaceuticals, Inc., Novartis International AG, Sandoz AG, Sanofi S.A., Sun Pharmaceutical Industries, Ltd., and Viatris Inc.

Market Segmentation & Coverage

This research report categorizes the Bronchitis Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:
  • Drug Type
    • Brand Drugs
    • Generic Drugs
    • Over-The-Counter Drugs
    • Prescription Drugs
  • Patient Demographics
    • Adults
      • Elderly
      • Middle-Aged Adults
      • Young Adults
    • Pediatrics
      • Adolescents
      • Children
      • Infants
    • Pregnant Women
  • Formulation
    • Inhalation Formulations
      • Dry Powder Inhalers
      • Metered-Dose Inhalers
    • Injectable Formulations
    • Oral Formulations
      • Capsules
      • Syrups
      • Tablets
    • Topical Formulations
  • Duration of Action
    • Extended-Release Drugs
    • Long-Acting Drugs
    • Short-Acting Drugs
  • Mechanism of Action
    • Analgesics
    • Antibiotics
    • Bronchodilators
      • Anticholinergics
      • Beta-Agonists
    • Mucolytics
  • Disease Severity
    • Acute Bronchitis
    • Chronic Bronchitis
  • End-User
    • Clinics
    • Homecare Settings
    • Hospitals
  • Route of Administration
    • Inhalation Route
    • Oral Route
    • Parenteral Route
  • Technology
    • Nebulizers
    • Smart Inhalers
  • Sales Channel
    • Hospital Pharmacies
    • Online Pharmacies
    • Retail Pharmacies
  • Treatment Duration
    • Long-Term Treatment
    • Short-Term Treatment
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States (California, Florida, Illinois, New York, Ohio, Pennsylvania, Texas)
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report provides a detailed overview of the market, exploring several key areas:

  • Market Penetration: A thorough examination of the current market landscape, featuring comprehensive data from leading industry players and analyzing their reach and influence across the market.
  • Market Development: The report identifies significant growth opportunities in emerging markets and assesses expansion potential within established segments, providing a roadmap for future development.
  • Market Diversification: In-depth coverage of recent product launches, untapped geographic regions, significant industry developments, and strategic investments reshaping the market landscape.
  • Competitive Assessment & Intelligence: A detailed analysis of the competitive landscape, covering market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, technological advancements, and innovations in manufacturing by key market players.
  • Product Development & Innovation: Insight into groundbreaking technologies, R&D efforts, and product innovations that will drive the market in future.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

  • What is the current size of the market, and how is it expected to grow?
  • Which products, segments, and regions present the most attractive investment opportunities?
  • What are the prevailing technology trends and regulatory factors influencing the market?
  • How do top vendors rank regarding market share and competitive positioning?
  • What revenue sources and strategic opportunities guide vendors' market entry or exit decisions?

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Greater emphasis on preventive healthcare encouraging the development of prophylactic medications for bronchitis
5.1.1.2. Pharmaceutical companies focusing on strategic partnerships and collaborations to expand their market presence
5.1.1.3. Expansion of telemedicine and remote consultations easing accessibility to bronchitis management solutions
5.1.2. Restraints
5.1.2.1. Intense competition from over-the-counter remedies and alternative therapies reducing prescription drug growth
5.1.2.2. Limited awareness and varying diagnosis rates affecting the demand for bronchitis drugs across regions
5.1.2.3. Regulatory challenges and approval timelines slowing down the introduction of new bronchitis treatments
5.1.3. Opportunities
5.1.3.1. Developing combination drug formulations addressing multiple symptoms for enhanced patient compliance
5.1.3.2. Exploring untapped geographies with high incidences of bronchitis and limited drug accessibility
5.1.3.3. Capitalizing on the growing demand for natural and herbal bronchitis treatment alternatives
5.1.4. Challenges
5.1.4.1. Rising prices of raw materials affecting the profit margins of bronchitis pharmaceuticals companies
5.1.4.2. Potential side effects leading to reduced consumer trust in bronchitis medications
5.1.4.3. Navigating patent expirations and the associated risk of generic competition
5.2. Market Segmentation Analysis
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental
6. Bronchitis Drugs Market, by Drug Type
6.1. Introduction
6.2. Brand Drugs
6.3. Generic Drugs
6.4. Over-The-Counter Drugs
6.5. Prescription Drugs
7. Bronchitis Drugs Market, by Patient Demographics
7.1. Introduction
7.2. Adults
7.2.1. Elderly
7.2.2. Middle-Aged Adults
7.2.3. Young Adults
7.3. Pediatrics
7.3.1. Adolescents
7.3.2. Children
7.3.3. Infants
7.4. Pregnant Women
8. Bronchitis Drugs Market, by Formulation
8.1. Introduction
8.2. Inhalation Formulations
8.2.1. Dry Powder Inhalers
8.2.2. Metered-Dose Inhalers
8.3. Injectable Formulations
8.4. Oral Formulations
8.4.1. Capsules
8.4.2. Syrups
8.4.3. Tablets
8.5. Topical Formulations
9. Bronchitis Drugs Market, by Duration of Action
9.1. Introduction
9.2. Extended-Release Drugs
9.3. Long-Acting Drugs
9.4. Short-Acting Drugs
10. Bronchitis Drugs Market, by Mechanism of Action
10.1. Introduction
10.2. Analgesics
10.3. Antibiotics
10.4. Bronchodilators
10.4.1. Anticholinergics
10.4.2. Beta-Agonists
10.5. Mucolytics
11. Bronchitis Drugs Market, by Disease Severity
11.1. Introduction
11.2. Acute Bronchitis
11.3. Chronic Bronchitis
12. Bronchitis Drugs Market, by End-User
12.1. Introduction
12.2. Clinics
12.3. Homecare Settings
12.4. Hospitals
13. Bronchitis Drugs Market, by Route of Administration
13.1. Introduction
13.2. Inhalation Route
13.3. Oral Route
13.4. Parenteral Route
14. Bronchitis Drugs Market, by Technology
14.1. Introduction
14.2. Nebulizers
14.3. Smart Inhalers
15. Bronchitis Drugs Market, by Sales Channel
15.1. Introduction
15.2. Hospital Pharmacies
15.3. Online Pharmacies
15.4. Retail Pharmacies
16. Bronchitis Drugs Market, by Treatment Duration
16.1. Introduction
16.2. Long-Term Treatment
16.3. Short-Term Treatment
17. Americas Bronchitis Drugs Market
17.1. Introduction
17.2. Argentina
17.3. Brazil
17.4. Canada
17.5. Mexico
17.6. United States
18. Asia-Pacific Bronchitis Drugs Market
18.1. Introduction
18.2. Australia
18.3. China
18.4. India
18.5. Indonesia
18.6. Japan
18.7. Malaysia
18.8. Philippines
18.9. Singapore
18.10. South Korea
18.11. Taiwan
18.12. Thailand
18.13. Vietnam
19. Europe, Middle East & Africa Bronchitis Drugs Market
19.1. Introduction
19.2. Denmark
19.3. Egypt
19.4. Finland
19.5. France
19.6. Germany
19.7. Israel
19.8. Italy
19.9. Netherlands
19.10. Nigeria
19.11. Norway
19.12. Poland
19.13. Qatar
19.14. Russia
19.15. Saudi Arabia
19.16. South Africa
19.17. Spain
19.18. Sweden
19.19. Switzerland
19.20. Turkey
19.21. United Arab Emirates
19.22. United Kingdom
20. Competitive Landscape
20.1. Market Share Analysis, 2023
20.2. FPNV Positioning Matrix, 2023
20.3. Competitive Scenario Analysis
20.4. Strategy Analysis & Recommendation
List of Figures
FIGURE 1. BRONCHITIS DRUGS MARKET MULTI-CURRENCY
FIGURE 2. BRONCHITIS DRUGS MARKET MULTI-LANGUAGE
FIGURE 3. BRONCHITIS DRUGS MARKET RESEARCH PROCESS
FIGURE 4. BRONCHITIS DRUGS MARKET SIZE, 2023 VS 2030
FIGURE 5. GLOBAL BRONCHITIS DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 6. GLOBAL BRONCHITIS DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL BRONCHITIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL BRONCHITIS DRUGS MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
FIGURE 9. GLOBAL BRONCHITIS DRUGS MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 10. GLOBAL BRONCHITIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2023 VS 2030 (%)
FIGURE 11. GLOBAL BRONCHITIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 12. GLOBAL BRONCHITIS DRUGS MARKET SIZE, BY FORMULATION, 2023 VS 2030 (%)
FIGURE 13. GLOBAL BRONCHITIS DRUGS MARKET SIZE, BY FORMULATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 14. GLOBAL BRONCHITIS DRUGS MARKET SIZE, BY DURATION OF ACTION, 2023 VS 2030 (%)
FIGURE 15. GLOBAL BRONCHITIS DRUGS MARKET SIZE, BY DURATION OF ACTION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 16. GLOBAL BRONCHITIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2023 VS 2030 (%)
FIGURE 17. GLOBAL BRONCHITIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 18. GLOBAL BRONCHITIS DRUGS MARKET SIZE, BY DISEASE SEVERITY, 2023 VS 2030 (%)
FIGURE 19. GLOBAL BRONCHITIS DRUGS MARKET SIZE, BY DISEASE SEVERITY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 20. GLOBAL BRONCHITIS DRUGS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
FIGURE 21. GLOBAL BRONCHITIS DRUGS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 22. GLOBAL BRONCHITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
FIGURE 23. GLOBAL BRONCHITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 24. GLOBAL BRONCHITIS DRUGS MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
FIGURE 25. GLOBAL BRONCHITIS DRUGS MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 26. GLOBAL BRONCHITIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2023 VS 2030 (%)
FIGURE 27. GLOBAL BRONCHITIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 28. GLOBAL BRONCHITIS DRUGS MARKET SIZE, BY TREATMENT DURATION, 2023 VS 2030 (%)
FIGURE 29. GLOBAL BRONCHITIS DRUGS MARKET SIZE, BY TREATMENT DURATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 30. AMERICAS BRONCHITIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 31. AMERICAS BRONCHITIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 32. UNITED STATES BRONCHITIS DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 33. UNITED STATES BRONCHITIS DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 34. ASIA-PACIFIC BRONCHITIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 35. ASIA-PACIFIC BRONCHITIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 36. EUROPE, MIDDLE EAST & AFRICA BRONCHITIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 37. EUROPE, MIDDLE EAST & AFRICA BRONCHITIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 38. BRONCHITIS DRUGS MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 39. BRONCHITIS DRUGS MARKET, FPNV POSITIONING MATRIX, 2023
List of Tables
TABLE 1. BRONCHITIS DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL BRONCHITIS DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL BRONCHITIS DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL BRONCHITIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. BRONCHITIS DRUGS MARKET DYNAMICS
TABLE 7. GLOBAL BRONCHITIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL BRONCHITIS DRUGS MARKET SIZE, BY BRAND DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL BRONCHITIS DRUGS MARKET SIZE, BY GENERIC DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL BRONCHITIS DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL BRONCHITIS DRUGS MARKET SIZE, BY PRESCRIPTION DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL BRONCHITIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL BRONCHITIS DRUGS MARKET SIZE, BY ADULTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL BRONCHITIS DRUGS MARKET SIZE, BY ELDERLY, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL BRONCHITIS DRUGS MARKET SIZE, BY MIDDLE-AGED ADULTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL BRONCHITIS DRUGS MARKET SIZE, BY YOUNG ADULTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL BRONCHITIS DRUGS MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL BRONCHITIS DRUGS MARKET SIZE, BY PEDIATRICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL BRONCHITIS DRUGS MARKET SIZE, BY ADOLESCENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL BRONCHITIS DRUGS MARKET SIZE, BY CHILDREN, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL BRONCHITIS DRUGS MARKET SIZE, BY INFANTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL BRONCHITIS DRUGS MARKET SIZE, BY PEDIATRICS, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL BRONCHITIS DRUGS MARKET SIZE, BY PREGNANT WOMEN, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL BRONCHITIS DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL BRONCHITIS DRUGS MARKET SIZE, BY INHALATION FORMULATIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL BRONCHITIS DRUGS MARKET SIZE, BY DRY POWDER INHALERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL BRONCHITIS DRUGS MARKET SIZE, BY METERED-DOSE INHALERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL BRONCHITIS DRUGS MARKET SIZE, BY INHALATION FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL BRONCHITIS DRUGS MARKET SIZE, BY INJECTABLE FORMULATIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL BRONCHITIS DRUGS MARKET SIZE, BY ORAL FORMULATIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL BRONCHITIS DRUGS MARKET SIZE, BY CAPSULES, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL BRONCHITIS DRUGS MARKET SIZE, BY SYRUPS, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL BRONCHITIS DRUGS MARKET SIZE, BY TABLETS, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL BRONCHITIS DRUGS MARKET SIZE, BY ORAL FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL BRONCHITIS DRUGS MARKET SIZE, BY TOPICAL FORMULATIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL BRONCHITIS DRUGS MARKET SIZE, BY DURATION OF ACTION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL BRONCHITIS DRUGS MARKET SIZE, BY EXTENDED-RELEASE DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL BRONCHITIS DRUGS MARKET SIZE, BY LONG-ACTING DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL BRONCHITIS DRUGS MARKET SIZE, BY SHORT-ACTING DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL BRONCHITIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL BRONCHITIS DRUGS MARKET SIZE, BY ANALGESICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL BRONCHITIS DRUGS MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL BRONCHITIS DRUGS MARKET SIZE, BY BRONCHODILATORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL BRONCHITIS DRUGS MARKET SIZE, BY ANTICHOLINERGICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL BRONCHITIS DRUGS MARKET SIZE, BY BETA-AGONISTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL BRONCHITIS DRUGS MARKET SIZE, BY BRONCHODILATORS, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL BRONCHITIS DRUGS MARKET SIZE, BY MUCOLYTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL BRONCHITIS DRUGS MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL BRONCHITIS DRUGS MARKET SIZE, BY ACUTE BRONCHITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL BRONCHITIS DRUGS MARKET SIZE, BY CHRONIC BRONCHITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL BRONCHITIS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL BRONCHITIS DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL BRONCHITIS DRUGS MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL BRONCHITIS DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL BRONCHITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL BRONCHITIS DRUGS MARKET SIZE, BY INHALATION ROUTE, BY REGION, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL BRONCHITIS DRUGS MARKET SIZE, BY ORAL ROUTE, BY REGION, 2018-2030 (USD MILLION)
TABLE 58. GLOBAL BRONCHITIS DRUGS MARKET SIZE, BY PARENTERAL ROUTE, BY REGION, 2018-2030 (USD MILLION)
TABLE 59. GLOBAL BRONCHITIS DRUGS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 60. GLOBAL BRONCHITIS DRUGS MARKET SIZE, BY NEBULIZERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 61. GLOBAL BRONCHITIS DRUGS MARKET SIZE, BY SMART INHALERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 62. GLOBAL BRONCHITIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 63. GLOBAL BRONCHITIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 64. GLOBAL BRONCHITIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 65. GLOBAL BRONCHITIS DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 66. GLOBAL BRONCHITIS DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
TABLE 67. GLOBAL BRONCHITIS DRUGS MARKET SIZE, BY LONG-TERM TREATMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 68. GLOBAL BRONCHITIS DRUGS MARKET SIZE, BY SHORT-TERM TREATMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 69. AMERICAS BRONCHITIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 70. AMERICAS BRONCHITIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 71. AMERICAS BRONCHITIS DRUGS MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 72. AMERICAS BRONCHITIS DRUGS MARKET SIZE, BY PEDIATRICS, 2018-2030 (USD MILLION)
TABLE 73. AMERICAS BRONCHITIS DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 74. AMERICAS BRONCHITIS DRUGS MARKET SIZE, BY INHALATION FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 75. AMERICAS BRONCHITIS DRUGS MARKET SIZE, BY ORAL FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 76. AMERICAS BRONCHITIS DRUGS MARKET SIZE, BY DURATION OF ACTION, 2018-2030 (USD MILLION)
TABLE 77. AMERICAS BRONCHITIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 78. AMERICAS BRONCHITIS DRUGS MARKET SIZE, BY BRONCHODILATORS, 2018-2030 (USD MILLION)
TABLE 79. AMERICAS BRONCHITIS DRUGS MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 80. AMERICAS BRONCHITIS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 81. AMERICAS BRONCHITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 82. AMERICAS BRONCHITIS DRUGS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 83. AMERICAS BRONCHITIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 84. AMERICAS BRONCHITIS DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
TABLE 85. AMERICAS BRONCHITIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 86. ARGENTINA BRONCHITIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 87. ARGENTINA BRONCHITIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 88. ARGENTINA BRONCHITIS DRUGS MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 89. ARGENTINA BRONCHITIS DRUGS MARKET SIZE, BY PEDIATRICS, 2018-2030 (USD MILLION)
TABLE 90. ARGENTINA BRONCHITIS DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 91. ARGENTINA BRONCHITIS DRUGS MARKET SIZE, BY INHALATION FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 92. ARGENTINA BRONCHITIS DRUGS MARKET SIZE, BY ORAL FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 93. ARGENTINA BRONCHITIS DRUGS MARKET SIZE, BY DURATION OF ACTION, 2018-2030 (USD MILLION)
TABLE 94. ARGENTINA BRONCHITIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 95. ARGENTINA BRONCHITIS DRUGS MARKET SIZE, BY BRONCHODILATORS, 2018-2030 (USD MILLION)
TABLE 96. ARGENTINA BRONCHITIS DRUGS MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 97. ARGENTINA BRONCHITIS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 98. ARGENTINA BRONCHITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 99. ARGENTINA BRONCHITIS DRUGS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 100. ARGENTINA BRONCHITIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 101. ARGENTINA BRONCHITIS DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
TABLE 102. BRAZIL BRONCHITIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 103. BRAZIL BRONCHITIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 104. BRAZIL BRONCHITIS DRUGS MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 105. BRAZIL BRONCHITIS DRUGS MARKET SIZE, BY PEDIATRICS, 2018-2030 (USD MILLION)
TABLE 106. BRAZIL BRONCHITIS DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 107. BRAZIL BRONCHITIS DRUGS MARKET SIZE, BY INHALATION FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 108. BRAZIL BRONCHITIS DRUGS MARKET SIZE, BY ORAL FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 109. BRAZIL BRONCHITIS DRUGS MARKET SIZE, BY DURATION OF ACTION, 2018-2030 (USD MILLION)
TABLE 110. BRAZIL BRONCHITIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 111. BRAZIL BRONCHITIS DRUGS MARKET SIZE, BY BRONCHODILATORS, 2018-2030 (USD MILLION)
TABLE 112. BRAZIL BRONCHITIS DRUGS MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 113. BRAZIL BRONCHITIS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 114. BRAZIL BRONCHITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 115. BRAZIL BRONCHITIS DRUGS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 116. BRAZIL BRONCHITIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 117. BRAZIL BRONCHITIS DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
TABLE 118. CANADA BRONCHITIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 119. CANADA BRONCHITIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 120. CANADA BRONCHITIS DRUGS MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 121. CANADA BRONCHITIS DRUGS MARKET SIZE, BY PEDIATRICS, 2018-2030 (USD MILLION)
TABLE 122. CANADA BRONCHITIS DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 123. CANADA BRONCHITIS DRUGS MARKET SIZE, BY INHALATION FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 124. CANADA BRONCHITIS DRUGS MARKET SIZE, BY ORAL FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 125. CANADA BRONCHITIS DRUGS MARKET SIZE, BY DURATION OF ACTION, 2018-2030 (USD MILLION)
TABLE 126. CANADA BRONCHITIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 127. CANADA BRONCHITIS DRUGS MARKET SIZE, BY BRONCHODILATORS, 2018-2030 (USD MILLION)
TABLE 128. CANADA BRONCHITIS DRUGS MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 129. CANADA BRONCHITIS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 130. CANADA BRONCHITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 131. CANADA BRONCHITIS DRUGS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 132. CANADA BRONCHITIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 133. CANADA BRONCHITIS DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
TABLE 134. MEXICO BRONCHITIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 135. MEXICO BRONCHITIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 136. MEXICO BRONCHITIS DRUGS MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 137. MEXICO BRONCHITIS DRUGS MARKET SIZE, BY PEDIATRICS, 2018-2030 (USD MILLION)
TABLE 138. MEXICO BRONCHITIS DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 139. MEXICO BRONCHITIS DRUGS MARKET SIZE, BY INHALATION FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 140. MEXICO BRONCHITIS DRUGS MARKET SIZE, BY ORAL FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 141. MEXICO BRONCHITIS DRUGS MARKET SIZE, BY DURATION OF ACTION, 2018-2030 (USD MILLION)
TABLE 142. MEXICO BRONCHITIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 143. MEXICO BRONCHITIS DRUGS MARKET SIZE, BY BRONCHODILATORS, 2018-2030 (USD MILLION)
TABLE 144. MEXICO BRONCHITIS DRUGS MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 145. MEXICO BRONCHITIS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 146. MEXICO BRONCHITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 147. MEXICO BRONCHITIS DRUGS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 148. MEXICO BRONCHITIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 149. MEXICO BRONCHITIS DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
TABLE 150. UNITED STATES BRONCHITIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 151. UNITED STATES BRONCHITIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 152. UNITED STATES BRONCHITIS DRUGS MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 153. UNITED STATES BRONCHITIS DRUGS MARKET SIZE, BY PEDIATRICS, 2018-2030 (USD MILLION)
TABLE 154. UNITED STATES BRONCHITIS DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 155. UNITED STATES BRONCHITIS DRUGS MARKET SIZE, BY INHALATION FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 156. UNITED STATES BRONCHITIS DRUGS MARKET SIZE, BY ORAL FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 157. UNITED STATES BRONCHITIS DRUGS MARKET SIZE, BY DURATION OF ACTION, 2018-2030 (USD MILLION)
TABLE 158. UNITED STATES BRONCHITIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 159. UNITED STATES BRONCHITIS DRUGS MARKET SIZE, BY BRONCHODILATORS, 2018-2030 (USD MILLION)
TABLE 160. UNITED STATES BRONCHITIS DRUGS MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 161. UNITED STATES BRONCHITIS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 162. UNITED STATES BRONCHITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 163. UNITED STATES BRONCHITIS DRUGS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 164. UNITED STATES BRONCHITIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 165. UNITED STATES BRONCHITIS DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
TABLE 166. UNITED STATES BRONCHITIS DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 167. ASIA-PACIFIC BRONCHITIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 168. ASIA-PACIFIC BRONCHITIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 169. ASIA-PACIFIC BRONCHITIS DRUGS MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 170. ASIA-PACIFIC BRONCHITIS DRUGS MARKET SIZE, BY PEDIATRICS, 2018-2030 (USD MILLION)
TABLE 171. ASIA-PACIFIC BRONCHITIS DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 172. ASIA-PACIFIC BRONCHITIS DRUGS MARKET SIZE, BY INHALATION FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 173. ASIA-PACIFIC BRONCHITIS DRUGS MARKET SIZE, BY ORAL FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 174. ASIA-PACIFIC BRONCHITIS DRUGS MARKET SIZE, BY DURATION OF ACTION, 2018-2030 (USD MILLION)
TABLE 175. ASIA-PACIFIC BRONCHITIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 176. ASIA-PACIFIC BRONCHITIS DRUGS MARKET SIZE, BY BRONCHODILATORS, 2018-2030 (USD MILLION)
TABLE 177. ASIA-PACIFIC BRONCHITIS DRUGS MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 178. ASIA-PACIFIC BRONCHITIS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 179. ASIA-PACIFIC BRONCHITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 180. ASIA-PACIFIC BRONCHITIS DRUGS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 181. ASIA-PACIFIC BRONCHITIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 182. ASIA-PACIFIC BRONCHITIS DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
TABLE 183. ASIA-PACIFIC BRONCHITIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 184. AUSTRALIA BRONCHITIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 185. AUSTRALIA BRONCHITIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 186. AUSTRALIA BRONCHITIS DRUGS MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 187. AUSTRALIA BRONCHITIS DRUGS MARKET SIZE, BY PEDIATRICS, 2018-2030 (USD MILLION)
TABLE 188. AUSTRALIA BRONCHITIS DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 189. AUSTRALIA BRONCHITIS DRUGS MARKET SIZE, BY INHALATION FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 190. AUSTRALIA BRONCHITIS DRUGS MARKET SIZE, BY ORAL FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 191. AUSTRALIA BRONCHITIS DRUGS MARKET SIZE, BY DURATION OF ACTION, 2018-2030 (USD MILLION)
TABLE 192. AUSTRALIA BRONCHITIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 193. AUSTRALIA BRONCHITIS DRUGS MARKET SIZE, BY BRONCHODILATORS, 2018-2030 (USD MILLION)
TABLE 194. AUSTRALIA BRONCHITIS DRUGS MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 195. AUSTRALIA BRONCHITIS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 196. AUSTRALIA BRONCHITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 197. AUSTRALIA BRONCHITIS DRUGS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 198. AUSTRALIA BRONCHITIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 199. AUSTRALIA BRONCHITIS DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
TABLE 200. CHINA BRONCHITIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 201. CHINA BRONCHITIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 202. CHINA BRONCHITIS DRUGS MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 203. CHINA BRONCHITIS DRUGS MARKET SIZE, BY PEDIATRICS, 2018-2030 (USD MILLION)
TABLE 204. CHINA BRONCHITIS DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 205. CHINA BRONCHITIS DRUGS MARKET SIZE, BY INHALATION FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 206. CHINA BRONCHITIS DRUGS MARKET SIZE, BY ORAL FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 207. CHINA BRONCHITIS DRUGS MARKET SIZE, BY DURATION OF ACTION, 2018-2030 (USD MILLION)
TABLE 208. CHINA BRONCHITIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 209. CHINA BRONCHITIS DRUGS MARKET SIZE, BY BRONCHODILATORS, 2018-2030 (USD MILLION)
TABLE 210. CHINA BRONCHITIS DRUGS MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 211. CHINA BRONCHITIS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 212. CHINA BRONCHITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 213. CHINA BRONCHITIS DRUGS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 214. CHINA BRONCHITIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 215. CHINA BRONCHITIS DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
TABLE 216. INDIA BRONCHITIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 217. INDIA BRONCHITIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 218. INDIA BRONCHITIS DRUGS MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 219. INDIA BRONCHITIS DRUGS MARKET SIZE, BY PEDIATRICS, 2018-2030 (USD MILLION)
TABLE 220. INDIA BRONCHITIS DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 221. INDIA BRONCHITIS DRUGS MARKET SIZE, BY INHALATION FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 222. INDIA BRONCHITIS DRUGS MARKET SIZE, BY ORAL FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 223. INDIA BRONCHITIS DRUGS MARKET SIZE, BY DURATION OF ACTION, 2018-2030 (USD MILLION)
TABLE 224. INDIA BRONCHITIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 225. INDIA BRONCHITIS DRUGS MARKET SIZE, BY BRONCHODILATORS, 2018-2030 (USD MILLION)
TABLE 226. INDIA BRONCHITIS DRUGS MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 227. INDIA BRONCHITIS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 228. INDIA BRONCHITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 229. INDIA BRONCHITIS DRUGS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 230. INDIA BRONCHITIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 231. INDIA BRONCHITIS DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
TABLE 232. INDONESIA BRONCHITIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 233. INDONESIA BRONCHITIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 234. INDONESIA BRONCHITIS DRUGS MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 235. INDONESIA BRONCHITIS DRUGS MARKET SIZE, BY PEDIATRICS, 2018-2030 (USD MILLION)
TABLE 236. INDONESIA BRONCHITIS DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 237. INDONESIA BRONCHITIS DRUGS MARKET SIZE, BY INHALATION FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 238. INDONESIA BRONCHITIS DRUGS MARKET SIZE, BY ORAL FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 239. INDONESIA BRONCHITIS DRUGS MARKET SIZE, BY DURATION OF ACTION, 2018-2030 (USD MILLION)
TABLE 240. INDONESIA BRONCHITIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 241. INDONESIA BRONCHITIS DRUGS MARKET SIZE, BY BRONCHODILATORS, 2018-2030 (USD MILLION)
TABLE 242. INDONESIA BRONCHITIS DRUGS MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 243. INDONESIA BRONCHITIS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 244. INDONESIA BRONCHITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 245. INDONESIA BRONCHITIS DRUGS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 246. INDONESIA BRONCHITIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 247. INDONESIA BRONCHITIS DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
TABLE 248. JAPAN BRONCHITIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 249. JAPAN BRONCHITIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 250. JAPAN BRONCHITIS DRUGS MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 251. JAPAN BRONCHITIS DRUGS MARKET SIZE, BY PEDIATRICS, 2018-2030 (USD MILLION)
TABLE 252. JAPAN BRONCHITIS DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 253. JAPAN BRONCHITIS DRUGS MARKET SIZE, BY INHALATION FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 254. JAPAN BRONCHITIS DRUGS MARKET SIZE, BY ORAL FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 255. JAPAN BRONCHITIS DRUGS MARKET SIZE, BY DURATION OF ACTION, 2018-2030 (USD MILLION)
TABLE 256. JAPAN BRONCHITIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 257. JAPAN BRONCHITIS DRUGS MARKET SIZE, BY BRONCHODILATORS, 2018-2030 (USD MILLION)
TABLE 258. JAPAN BRONCHITIS DRUGS MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 259. JAPAN BRONCHITIS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 260. JAPAN BRONCHITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 261. JAPAN BRONCHITIS DRUGS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 262. JAPAN BRONCHITIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 263. JAPAN BRONCHITIS DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
TABLE 264. MALAYSIA BRONCHITIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 265. MALAYSIA BRONCHITIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 266. MALAYSIA BRONCHITIS DRUGS MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 267. MALAYSIA BRONCHITIS DRUGS MARKET SIZE, BY PEDIATRICS, 2018-2030 (USD MILLION)
TABLE 268. MALAYSIA BRONCHITIS DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 269. MALAYSIA BRONCHITIS DRUGS MARKET SIZE, BY INHALATION FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 270. MALAYSIA BRONCHITIS DRUGS MARKET SIZE, BY ORAL FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 271. MALAYSIA BRONCHITIS DRUGS MARKET SIZE, BY DURATION OF ACTION, 2018-2030 (USD MILLION)
TABLE 272. MALAYSIA BRONCHITIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 273. MALAYSIA BRONCHITIS DRUGS MARKET SIZE, BY BRONCHODILATORS, 2018-2030 (USD MILLION)
TABLE 274. MALAYSIA BRONCHITIS DRUGS MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 275. MALAYSIA BRONCHITIS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 276. MALAYSIA BRONCHITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 277. MALAYSIA BRONCHITIS DRUGS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 278. MALAYSIA BRONCHITIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 279. MALAYSIA BRONCHITIS DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
TABLE 280. PHILIPPINES BRONCHITIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 281. PHILIPPINES BRONCHITIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 282. PHILIPPINES BRONCHITIS DRUGS MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 283. PHILIPPINES BRONCHITIS DRUGS MARKET SIZE, BY PEDIATRICS, 2018-2030 (USD MILLION)
TABLE 284. PHILIPPINES BRONCHITIS DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 285. PHILIPPINES BRONCHITIS DRUGS MARKET SIZE, BY INHALATION FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 286. PHILIPPINES BRONCHITIS DRUGS MARKET SIZE, BY ORAL FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 287. PHILIPPINES BRONCHITIS DRUGS MARKET SIZE, BY DURATION OF ACTION, 2018-2030 (USD MILLION)
TABLE 288. PHILIPPINES BRONCHITIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 289. PHILIPPINES BRONCHITIS DRUGS MARKET SIZE, BY BRONCHODILATORS, 2018-2030 (USD MILLION)
TABLE 290. PHILIPPINES BRONCHITIS DRUGS MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 291. PHILIPPINES BRONCHITIS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 292. PHILIPPINES BRONCHITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 293. PHILIPPINES BRONCHITIS DRUGS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 294. PHILIPPINES BRONCHITIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 295. PHILIPPINES BRONCHITIS DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
TABLE 296. SINGAPORE BRONCHITIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 297. SINGAPORE BRONCHITIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 298. SINGAPORE BRONCHITIS DRUGS MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 299. SINGAPORE BRONCHITIS DRUGS MARKET SIZE, BY PEDIATRICS, 2018-2030 (USD MILLION)
TABLE 300. SINGAPORE BRONCHITIS DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 301. SINGAPORE BRONCHITIS DRUGS MARKET SIZE, BY INHALATION FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 302. SINGAPORE BRONCHITIS DRUGS MARKET SIZE, BY ORAL FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 303. SINGAPORE BRONCHITIS DRUGS MARKET SIZE, BY DURATION OF ACTION, 2018-2030 (USD MILLION)
TABLE 304. SINGAPORE BRONCHITIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 305. SINGAPORE BRONCHITIS DRUGS MARKET SIZE, BY BRONCHODILATORS, 2018-2030 (USD MILLION)
TABLE 306. SINGAPORE BRONCHITIS DRUGS MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 307. SINGAPORE BRONCHITIS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 308. SINGAPORE BRONCHITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 309. SINGAPORE BRONCHITIS DRUGS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 310. SINGAPORE BRONCHITIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 311. SINGAPORE BRONCHITIS DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
TABLE 312. SOUTH KOREA BRONCHITIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 313. SOUTH KOREA BRONCHITIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 314. SOUTH KOREA BRONCHITIS DRUGS MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 315. SOUTH KOREA BRONCHITIS DRUGS MARKET SIZE, BY PEDIATRICS, 2018-2030 (USD MILLION)
TABLE 316. SOUTH KOREA BRONCHITIS DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 317. SOUTH KOREA BRONCHITIS DRUGS MARKET SIZE, BY INHALATION FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 318. SOUTH KOREA BRONCHITIS DRUGS MARKET SIZE, BY ORAL FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 319. SOUTH KOREA BRONCHITIS DRUGS MARKET SIZE, BY DURATION OF ACTION, 2018-2030 (USD MILLION)
TABLE 320. SOUTH KOREA BRONCHITIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 321. SOUTH KOREA BRONCHITIS DRUGS MARKET SIZE, BY BRONCHODILATORS, 2018-2030 (USD MILLION)
TABLE 322. SOUTH KOREA BRONCHITIS DRUGS MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 323. SOUTH KOREA BRONCHITIS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 324. SOUTH KOREA BRONCHITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 325. SOUTH KOREA BRONCHITIS DRUGS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 326. SOUTH KOREA BRONCHITIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 327. SOUTH KOREA BRONCHITIS DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
TABLE 328. TAIWAN BRONCHITIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 329. TAIWAN BRONCHITIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 330. TAIWAN BRONCHITIS DRUGS MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 331. TAIWAN BRONCHITIS DRUGS MARKET SIZE, BY PEDIATRICS, 2018-2030 (USD MILLION)
TABLE 332. TAIWAN BRONCHITIS DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 333. TAIWAN BRONCHITIS DRUGS MARKET SIZE, BY INHALATION FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 334. TAIWAN BRONCHITIS DRUGS MARKET SIZE, BY ORAL FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 335. TAIWAN BRONCHITIS DRUGS MARKET SIZE, BY DURATION OF ACTION, 2018-2030 (USD MILLION)
TABLE 336. TAIWAN BRONCHITIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 337. TAIWAN BRONCHITIS DRUGS MARKET SIZE, BY BRONCHODILATORS, 2018-2030 (USD MILLION)
TABLE 338. TAIWAN BRONCHITIS DRUGS MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 339. TAIWAN BRONCHITIS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 340. TAIWAN BRONCHITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 341. TAIWAN BRONCHITIS DRUGS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 342. TAIWAN BRONCHITIS DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 343. TAIWAN BRONCHITIS DRUGS MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
TABLE 344. THAILAND BRONCHITIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 345. THAILAND BRONCHITIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 346. THAILAND BRONCHITIS DRUGS MARKET SIZE, BY ADULTS, 2018-2030 (USD MILLION)
TABLE 347. THAILAND BRONCHITIS DRUGS MARKET SIZE, BY PEDIATRICS, 2018-2030 (USD MILLION)
TABLE 348. THAILAND BRONCHITIS DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 349. THAILAND BRONCHITIS DRUGS MARKET SIZE, BY

Companies Mentioned

  • Alembic Pharmaceuticals Ltd.
  • Apotex Inc.
  • Boehringer Ingelheim International GmbH
  • DLC Laboratories, Inc.
  • Dr. Reddy's Laboratories Ltd.
  • Fresenius Kabi
  • GlaxoSmithKline Pharmaceuticals Ltd.
  • Glenmark Pharmaceuticals Ltd.
  • Jamp Pharma Corporation
  • Marlex Pharmaceuticals, Inc.
  • Novartis International AG
  • Sandoz AG
  • Sanofi S.A.
  • Sun Pharmaceutical Industries, Ltd.
  • Viatris Inc.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages188
PublishedNovember 2024
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 1.68 billion
Forecasted Market Value ( USD ) by 2030 $ 2.96 billion
Compound Annual Growth Rate9.7%
Regions CoveredGlobal
No. of Companies Mentioned15

Related Topics

Related Reports

Bronchitis - Market Insight, Epidemiology and Market Forecast - 2034 - Product Image

Bronchitis - Market Insight, Epidemiology and Market Forecast - 2034

  • Report
  • 200 Pages
  • Global
From
Bronchitis Treatment Market by Indication, Treatment, Class of Drugs, End User - Global Forecast 2025-2030 - Product Image

Bronchitis Treatment Market by Indication, Treatment, Class of Drugs, End User - Global Forecast 2025-2030

  • Report
  • 197 Pages
  • Global
From
Bronchitis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034 - Product Image

Bronchitis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

  • Report
  • 135 Pages
  • Global
From
Chronic Bronchitis - Market Insight, Epidemiology and Market Forecast - 2034 - Product Image

Chronic Bronchitis - Market Insight, Epidemiology and Market Forecast - 2034

  • Report
  • 200 Pages
  • Global
From
Bronchitis Treatment Global Market Report 2024 - Product Image

Bronchitis Treatment Global Market Report 2024

  • Report
  • 200 Pages
  • Global
From

About the Bronchitis Drugs Market

The Bronchitis Drugs market is a segment of the pharmaceutical industry that focuses on the development and sale of medications used to treat bronchitis. Bronchitis is an inflammation of the bronchial tubes, which are the airways that carry air to and from the lungs. Bronchitis drugs are used to reduce inflammation, reduce mucus production, and improve breathing. Common bronchitis drugs include bronchodilators, corticosteroids, and antibiotics. Bronchitis drugs are sold by a variety of companies, including GlaxoSmithKline, Merck & Co., Pfizer, and AstraZeneca. These companies produce a range of bronchitis drugs, including Advair, Symbicort, and Flovent. Other companies, such as Boehringer Ingelheim, Novartis, and Sanofi, also produce bronchitis drugs. Show Less Read more

Copyright © 2002-2024 Research and Markets. All Rights Reserved.